Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
GLAXO.NSthis companyGlaxoSmithKline Pharmaceuticals Limited	₹2,710.00	37.33×	17.06×	10.12×	25.49×	32.4%	43.6%	33.0%	27.1%	45.7%	36.3%	2.5%	0.01×	-0.72×	461.5×	2.03×	1.8%	4	—	2	C+
ABBOTINDIA.NSAbbott India Limited	₹26,680.00	35.48×	11.53×	7.95×	24.37×	179.8%	36.2%	26.5%	22.4%	32.5%	27.0%	3.0%	0.04×	-0.96×	97.31×	2.55×	1.8%	4	22.4	2	C
ASTRAZEN.NSAstraZeneca Pharma India Limited	₹6,529.00	103.53×	22.24×	8.53×	66.87×	74.4%	26.5%	10.3%	8.2%	21.5%	17.0%	0.0%	0.13×	-1.18×	51.99×	1.77×	0.4%	3	—	2	C+
AUROPHARMA.NSAurobindo Pharma Limited	₹1,855.30	21.62×	2×	2.25×	10.17×	130.3%	39.2%	15.1%	10.4%	9.2%	7.3%	3.7%	0.21×	-0.25×	13.22×	1.81×	0.3%	5	—	2	B-
CIPLA.NSCipla Limited	₹1,403.80	25.49×	2.87×	3.51×	15.19×	112.4%	42.7%	16.7%	13.8%	11.3%	9.8%	2.6%	0.02×	-0.06×	86.67×	3.44×	1.3%	4	9.92	4	A-
DRREDDY.NSDr. Reddy's Laboratories Limited	₹1,385.00	24.38×	2.77×	3.11×	14.13×	25.1%	52.8%	13.8%	12.8%	11.4%	7.5%	2.9%	0.24×	0.94×	12.42×	1.8×	0.6%	7	5.66	3	B+
Peer median	—	25.49×	2.87×	3.51×	15.19×	112.4%	39.2%	15.1%	12.8%	11.4%	9.8%	2.9%	0.13×	-0.25×	51.99×	1.81×	0.6%	4	9.92	2	—